The Partnership for Accelerating Cancer Therapies.

Area of Science:

• Oncology
• Immunology
• Biomarker Development
• Clinical Trials

Background:

• The Cancer Moonshot initiative aims to accelerate cancer research and improve patient outcomes.
• Public-private partnerships are crucial for addressing complex challenges in cancer therapy development.
• The need for standardized biomarkers and robust clinical data is a significant hurdle in advancing cancer immunotherapies.

Purpose of the Study:

• To establish a 5-year, $220 million public-private research collaboration focused on cancer therapies.
• To identify and develop standardized biomarkers and clinical data for immunotherapy selection and testing.
• To accelerate the development and delivery of effective immunotherapies to cancer patients.

Main Methods:

• Formation of a precompetitive research collaboration involving government agencies and pharmaceutical companies.
• Systematic, cross-sector effort to identify and validate biomarkers.
• Development of standardized clinical data collection and analysis protocols.

Main Results:

• Established a significant public-private partnership with substantial funding ($220 million) over 5 years.
• Initiated a systematic approach to biomarker and clinical data standardization.
• Focused on selecting and testing promising immunotherapies for diverse cancer types.

Conclusions:

• The Partnership for Accelerating Cancer Therapies is poised to enhance the efficiency of immunotherapy development.
• Standardized biomarkers and data are key to improving the selection and success of cancer treatments.
• This collaborative effort aims to bring more effective cancer therapies to patients sooner.